Respiratory Syncytial Virus Infection in Infants: A Significant Challenge for Optimal Care

Journal of Perinatal and Neonatal Nursing

Volumn 10, Issue 2, 1996, Pages 72-87

  Bozzette, Maryann ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Infants; Infection; Respiratory; Respiratory syncytial virus; Viral

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN;

DISEASE TRANSMISSION; HUMAN; INFANT; NEWBORN; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; VIRUS INFECTION;

ANTIVIRAL AGENTS; HUMANS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RIBAVIRIN; RISK FACTORS;

EID: 0030237785     PISSN: 08932190     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005237-199609000-00007     Document Type: Article

References (44)

1. Hemming VG. Viral respiratory disease in children: Classification, etiology, epidemiology, and risk factors. J Pediatr. 1994; 124:S13-S16.
2. Levin MJ. Treatment and prevention options for respiratory syncytial virus infections. J Pediatr. 1994;124:S22-S27.
3. Lugo RA, Nahata MC. Pathogenesis and treatment of bronchiolitis. Clin Pharm. 1993; 12:95-116.
4. Panitch HB, Callahan CWJ, Maj DO, Usar MC, Schidlow DV. Bronchiolitis in children. Clin Chest Med. 1993;14:715-731.
5. Groothuis JR, Simoes EAF, Hemming VG. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics. 1995;95:463-467.
6. Everard ML. Bronchiolitis: Origins and optimal management. Drugs. 1995;49:885-896.
7. Chiocca EM. RSV and the high-risk infant. Pediatr Nurs. 1994;20:565-568.
8. Meert K, Heidemann J, Abella B, Sarnaik A. Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med. 1990;18:1357-1359.
9. Rakshi K, Couriel JM. Management of acute bronchiolitis. Arch Dis Child. 1994; 71:463-469.
10. Khan JY, Kerr SJ, Tometzki L, et al. Role of ECMO in the treatment of respiratory syncytial virus bronchiolitis: A collaborative report. Arch Dis Child. 1995;73:F91-F94.
11. Meisner HC. Economic impact of viral respiratory disease in children. J Pediatr. 1994;124:S17-S21.
12. Filipell MB, Rearick T. Respiratory syncytial virus. Nurs Clin North Am. 1993;23:651-672.
13. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev. 1995;8:22-33.
14. Lindergren C, Jing L, Graham B, Grogaard J, Sundell H. Respiratory syncytial virus infection reinforces reflex apnea in young lambs. Pediatr Res. 1992;31:381-385.
15. Welliver RC, Duffy L. The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing and pulmonary function at age 7-8 years. Pediatr Pulmonol. 1993;15:19-27.
16. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: A prospective cohort study with matched controls. Pediatrics. 1995; 95(4):500-505.
17. Walker TA, Khurana S, Tilden SJ. Viral respiratory infections. Pediatr Clin North Am. 1994;41:1365-1381.
18. Englund JA. Passive protection against respiratory syncytial virus: The role of maternal antibody. Pediatr Infect Dis J. 1994; 13:449-453.
19. Groothuis JR. Role of antibody and use of respiratory syncytial virus (RSV) immune globulin to prevent severe RSV disease in high-risk children. J Pediatr. 1994;124: S28-S32.
20. Yamazaki J, Tsutsumi H, Matsuda J, Nagai K, Ogra PL. Effect of maternal antibody on IgA antibody response in nasopharyngeal secretions in infants and children during primary respiratory syncytial virus infection. J Gen Virol. 1994;75:2115-2119.
21. Tsutsumi H, Matsuda K, Yamazaki H, Ogra PL, Chiba S. Different kinetics of antibody responses between IgA and IgG classes in nasopharyngeal secretions in infants and children during primary respiratory syncytial virus infection. Acta Paediatr Jpn. 1995; 37:464-468.
22. Murguia de Sierr T, Kumar ML, Wasser TE, Murphy BR, Subbarao EK. Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr. 1993;122:787-791.
23. Midulla F, Villani A, Puanuska JR, et al. Respiratory syncytial virus lung infection in infants: Immunoregulatory role of infected alveolar macrophages. J Infect Dis. 1993;168:1515-1519.
24. Welliver RC. RSV and chronic asthma. Lancet. 1995;346:789-790.
25. Harris J, Culp S, Nicolayson T, Waterman C, Whitehorn SL. Respiratory syncytial virus: A pediatric nursing plan of care. J Pediatr Nurs. 1992;7:128-132.
26. Corey MA, Rudy Clore E. Management of the infant with respiratory syncytial virus. J Pediatr Nurs. 1991;6:93-98.
27. Garea MT, Lopez JM, Perez-del-Molino ML, Coira A, Parodo F. Comparison of a new commercial enzyme immunoassay for rapid detection of respiratory syncytial virus. Eur J Clin Microbiol Infect Dis. 1992; 11:175-177.
28. Balfour-Lynn IM, Girdhar DR, Atiken C. Diagnosing respiratory syncytial virus by nasal lavage. Arch Dis Child. 1995;72:58-59.
29. Tepper RS, Rosenberg D, Eigen H, Reister T. Bronchodilator responsiveness in infants with bronchiolitis. Pediatr Pulmonol. 1994; 17:81-85.
30. Hammer J, Numa A, Newth CJ. Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. J Pediatr. 1995;127:485-490.
31. Chowdhury D, al-Howesi M, Khalil M, alFrayh AS, Choudhury S, Ramia S. The role of bronchodilators in the management of bronchiolitis: A clinical trial. Ann Trop Paediatr. 1995;15:77-84.
32. Ameratunga SM, Lennon DR, Asher MJ, Spinetto J, Anderson B. Ribavirin therapy of respiratory syncytial virus infections. N Z Med J. 1994;107:180-182.
33. Runton N. Ribavirin. Neonat Network. 1993;12:75-77.
34. Smith DW, Frankel LR, Mathers LH, Tang MRCP, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991;325:24-29.
35. Adams DA. Ribavirin administration via scavenger vacuum systems in the treatment of respiratory syncytial virus (RSV). J Pediatr Nurs. 1994;9:51-54.
36. Janai HK, Stutman HR, Zaleska M, et al. Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis. J Infect Dis. 1993;12: 214-218.
37. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of respiratory syncytial virus in cotton rats. Am J Pathol. 1978;93:771-792.
38. Muelenaer PM, Henderson FW, Hemming VG, et al. Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus. J Infect Dis. 1991;164:15-21.
39. Murphy BR, Hall SL, Kulkarni AB, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 1994;32:13-36.
40. Tristram DA, Welliver RC, Hogerman DA, Hildreth SW, Paradiso P. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: Evaluation of antibody persistence and possible disease enhancement. Vaccine. 1994;12:551-556.
41. Schindler LW. Understanding the Immune System. Washington, DC: National Institutes of Health; 1993.
42. Crowe JEJ, Murphy BR, Canock RM, Williamson RA, Barbas ICF, Burton DR. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci USA. 1994;91: 1386-1390.
43. Makela MJ, Ruuskanen O, Ogra PL. Treatment of respiratory syncytial virus infections in children. Ann Med. 1994;26:341-343.
44. Leclerc F, Riou Y, Martinot A, et al. Inhaled nitric oxide for a severe respiratory syncytial virus infection in an infant with bronchopulmonary dysplasia. Intensive Care Med. 1994;20:511-512.